Mabpharm opens $195m HK IPO, Hansoh kicks off PDIE
Biopharmaceuticals company Mabpharm launched bookbuilding for its up to HK$1.53bn ($195m) flotation, while Hansoh Pharmaceutical Group set pre-marketing in motion for its Hong Kong listing.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: